ImmunityBio, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $113.3 | $14.7 | $0.6 | $0.2 | $0.9 |
| Operating income | -$256.0 | -$344.2 | -$362.2 | -$351.3 | -$330.3 |
| Net income | -$351.4 | -$413.6 | -$583.2 | -$416.6 | -$346.8 |
| Cash Flow Statement | |||||
| Free cash flow | -$308.8 | -$398.1 | -$397.3 | -$415.7 | -$308.0 |
| Share repurchases | — | — | — | — | $0.0 |
Shares outstanding 1.1B · Free float 67.7%
Annual filing data through FY ended December 31, 2025; float as of September 27, 2026.
Earnings
Other Coverage
October 14, 2026
Theme Survey
Drug Pricing and PBM Scrutiny: Medicare Rulemaking Gains Detail
October 6, 2026
Theme Survey
Tariffs and Trade Restrictions: Build-A-Bear Names Cost Impact
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back